Headlands Technologies’s Ascendis Pharma A/S ASND Stock Holding History

Headlands Technologies’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Sell	898 -10,666	-92%	-$2.39M	0.02%	592
2025 Q4	$2.47M	Buy	+11,564	New	+$2.39M	0.21%	105
2025 Q3	–	Sell	-1,196	Closed	-$206K	–	647
2025 Q2	$206K	Buy	+1,196	New	+$195K	0.02%	458
2024 Q4	–	Sell	-699	Closed	-$104K	–	1194
2024 Q3	$104K	Sell	699 -5,639	-89%	-$762K	0.01%	660
2024 Q2	$864K	Buy	+6,338	New	+$862K	0.09%	189
2024 Q1	–	Sell	-121	Closed	-$15.2K	–	1242
2023 Q4	$15.2K	Buy	+121	New	+$12.1K	﹤0.01%	708

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Headlands Technologies's ASND Position: Q1 2026 in Review

Headlands Technologies reduced its Ascendis Pharma A/S (ASND) stake by 92% in Q1 2026, selling an estimated $2.39M and leaving 898 shares worth $205K. The position accounts for 0.02% of the portfolio, ranked #592.

Headlands Technologies first reported a position in ASND in Q4 2023 and has held it in 6 quarters since. The position peaked at $2.47M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Headlands Technologies held 898 shares of Ascendis Pharma A/S worth $205K as of Q1 2026.
Headlands Technologies sold 10,666 Ascendis Pharma A/S shares in Q1 2026, an estimated $2.39M.
Ascendis Pharma A/S made up 0.02% of Headlands Technologies's portfolio in Q1 2026, its #592 holding.
Headlands Technologies first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 6 quarters since.
Headlands Technologies's Ascendis Pharma A/S position peaked at $2.47M in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.